Roche to buy gene therapy firm Spark for $4.8 billion
Roche is to buy gene therapy firm Spark Therapeutics for $4.8 billion, adding an already-approved treatment for inherited blindness to its portfolio, and boosting its pipeline with a series of potential rare disease drugs.
The Swiss pharma has reached a deal to buy Spark in an all-cash transaction at a price of $114.50 per share, a premium of 122% to the US company’s closing price on Friday evening.
Read more...